Novartis faces market decline following clinical research setbacks

Novartis has experienced a significant market setback, with its stock price dropping by over 10 percent in a single day, resulting in a loss of approximately 24 billion Swiss francs in market value. This decline heavily impacted the Swiss Market Index (SMI).

The downturn follows a series of clinical research setbacks. The company reported failures in its drug pipeline, including Pelacarsen for cardiovascular diseases and Del-Desiran for a genetic muscle disease. These failures have raised questions regarding the 12-billion-dollar acquisition of Avidity Biosciences, which was intended to provide a new platform for drug development.

Despite these challenges, CEO Vas Narasimhan has maintained his strategic focus on high-margin, patent-protected pharmaceuticals, a direction achieved through the previous spin-offs of Alcon and Sandoz. While Novartis faces volatility, its former subsidiary Sandoz is seeing growth in the generics sector and is expected to be included in the SMI.